The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial.
 
Takuya Fukushima
Speakers' Bureau - Astellas Pharma; AstraZeneca; Kyowa Kirin International; Meiji Seika Kaisha; Takeda
Research Funding - Daiichi Sankyo/UCB Japan
 
Kunihiro Tsukasaki
Consulting or Advisory Role - Chugai Pharma; Eisai; Meiji Seika Kaisha; Takeda
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo; HUYA Bioscience International; Kyowa Kirin; Meiji Seika Kaisha; Regeneron
 
Ryunosuke Machida
No Relationships to Disclose
 
Dai Maruyama
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Genmab; Janssen; Kyowa Kirin; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Sanofi; SymBio Pharmaceuticals; Takeda; Zenyaku Kogyo
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Genmab; Janssen; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Genmab (Inst); Janssen (Inst); Kyowa Kirin (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Shinichi Makita
Honoraria - Abbvie; AstraZeneca; Celgene Cancer Care Links/BMS; Chugai Pharma; Daiichi Sankyo; Genmab; Gilead Sciences; Takeda
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Celgene Cancer Care Links/BMS; Chugai Pharma; Daiichi Sankyo; Genmab; Gilead Sciences; Takeda
 
Shigeru Kusumoto
Honoraria - Chugai Pharma; Daiichi Sankyo; Janssen; Kyowa Kirin
Consulting or Advisory Role - Lilly Japan
Research Funding - Chugai Pharma; Daiichi Sankyo; Janssen
 
Shinsuke Iida
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Novartis; Otsuka; Pfizer
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Takeda (Inst)
 
Masahito Tokunaga
No Relationships to Disclose
 
Yasushi Miyazaki
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Nippon Shinyaku; Novartis; Sumitomo Pharma Oncology
 
Makoto Yoshimitsu
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; CSL Behring; Daiichi Sankyo; Meiji Seika Kaisha; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Otsuka; Sanofi; Takeda
 
Ilseung Choi
No Relationships to Disclose
 
Sawako Nakachi
No Relationships to Disclose
 
Kana Miyazaki
Honoraria - Abbvie; Asahi Kasei; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Incyte; Janssen; Meiji Seika Kaisha; Nippon Shinyaku; Novartis; SymBio Pharmaceuticals
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Junya Makiyama
Consulting or Advisory Role - Takeda
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Janssen; Kyowa Kirin; Meiji Seika Kaisha; Ono Yakuhin; Otsuka; Sanofi; SymBio Pharmaceuticals; Takeda
 
Kisato Nosaka
Honoraria - Abbvie; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Meiji Seika Kaisha; Ohara Pharmaceutical
Research Funding - Chugai Pharma; Kyowa Kirin
 
Hiroo Katsuya
Honoraria - Bristol Myers Squibb
Speakers' Bureau - Daiichi Sankyo/UCB Japan; Lilly
 
Toshiro Kawakita
No Relationships to Disclose
 
Taro Shibata
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; CMIC Co., Ltd.; Kyowa Kirin Co., Ltd.; m3.com
 
Hirokazu Nagai
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; CSL Behring; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Meiji Seika Kaisha; Mundipharma; Novartis; Ono Pharmaceutical; Sumitomo Pharma Oncology; Sumitomo Pharma Oncology; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab (Inst); HUYA Bioscience International (Inst); Incyte Japan (Inst); Janssen (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Solasia Pharma (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)